Lyell Immunopharma announced positive clinical updates from its PiNACLE trial for ronde-cel, a CAR T-cell therapy targeting large B-cell lymphoma, showing a 91% overall response rate and durable complete responses. The company plans pivotal data release and FDA Biologics License Application submission in 2027. Additionally, Lyell completed technology transfer for its LYL273 therapy and secured $80 million in private financing to fund operations into 2028. These developments position Lyell to advance its next-generation cancer therapies toward commercialization.
Lyell Immunopharma's recent clinical and financial updates come as 108 of 150 Health-sector US stocks tradable on Pluang rose today. For readers following the Health sector, here is Pluang's market snapshot as of Nov 05, 2026 04:11 WIB: Acadia Healthcare Company Inc (ACHC) surged 16.68% to USD 34.56 with 89% sell orders, Moderna, Inc. (MRNA) gained 12.97% to USD 258.08 with 81% sell orders, and Bruker Corporation (BRKR) increased 12.87% to USD 63.77 with balanced buy/sell activity and a typical hold time of 13 days.
The global polypropylene market is projected to grow from 102.7 million tons in 2026 to 139.2 million tons by 2032, with a CAGR of 5.14%. Growth is fueled by rising demand for lightweight automotive parts, mono-material flexible packaging, and high-m...
At the 2026 Chery International User Summit, Chery Auto showcased its new physical AI technology built on decades of automotive safety data and engineering. Their CheryMind AI model and CHERY All-World Engine support autonomous robots, robotaxis, and...
NOVAGOLD shareholders approved a transaction for New NOVAGOLD to acquire the remaining 40% interest in the Donlin Gold project from Paulson Advisers, increasing NOVAGOLD's ownership from 60% to 100%. This consolidation makes New NOVAGOLD the ultimate...
Fox Factory Holding Corp. has appointed Troy Henige as its new Chief Technology Officer (CTO) to lead the company's technology vision, strategy, and product roadmap. This new role aims to enhance innovation, connect engineering strengths across the c...
Sandisk Corporation is rated as a Strong Buy with a revised price target of $3,356, reflecting its deep undervaluation in the market. Despite strong Q1 2027 results, the company trades at a very low forward PEG ratio of 0.12x. The analyst estimates a...
